Novo Nordisk has launched an oral version of its Wegovy weight-loss drug in the UK, available privately through pharmacies without a prescription requirement for the private market. This follows the established injectable Wegovy brand and marks a meaningful step in making GLP-1 therapies more accessible — pills remove the barrier of self-injection that deters some patients.

NVO is already a dominant GLP-1 franchise with $309B in reported revenue (FY2025), 81% gross margins, and $23.03 diluted EPS, reflecting the extraordinary profitability of the semaglutide platform. The UK oral launch potentially opens a large new patient population — those unwilling to inject — and adds a recurring daily-pill revenue stream alongside the existing injectable business.

However, NVO's stock has already corrected sharply from its 2024 peaks, partly on concerns about competitive pressure from Eli Lilly's tirzepatide, pipeline setbacks, and pricing pressure risks. The oral pill launch is a positive catalyst but is not a surprise — it had been widely anticipated, and the UK is a relatively small market compared to the US opportunity where regulatory timelines differ.

The bull case rests on oral GLP-1 dramatically expanding the total addressable market if patient uptake is strong, with NVO's proven manufacturing scale and brand recognition. The bear case is that the stock is already discounting a competitive pipeline erosion scenario, and a UK-only private-pay launch is too small to move the needle on a company of this scale.

Watch for US FDA oral semaglutide approval timelines, Lilly pipeline updates, and any data on oral vs injectable efficacy comparisons — those are the real valuation-moving catalysts.